20th International Congress » Huntington's disease

12:00pm-1:30pm

A health cost analysis for Huntington disease in Peru

G. Silva-Paredes, M. Cornejo-Olivas, M. Inca-Martinez, K. Espinoza-Huertas, A. Vishnevetsky, P. Mazzetti, R. Urbanos-Garrido (Lima, Peru)

12:00pm-1:30pm

A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval

D. Stamler, E. Offman, M. Bradbury, L. De Boer (La Jolla, CA, USA)

12:00pm-1:30pm

Abnormal intrinsic brain activity reveals neural correlates of impaired cognitive function in early stage of Huntington’s disease (HD): A resting-state fMRI study

W. Liu, J. Yang, K. Chen, C. Luo, J.M. Burgunder, Q. Gong, H. Shang (Chengdu, People's Republic of China)

12:00pm-1:30pm

Altered cerebello-thalamo-cortical pathway in Huntington’s disease

J.F. Martín-Rodríguez, M. Gómez-Crespo, M.T. Cáceres-Redondo, L. Vargas-González, F.J. Palomar, P. Porcacchia, P. Álvarez de Toledo, J.M. Oropesa-Ruiz, F. Carrillo, I. Huertas-Fernández, S. Jesús, P. Mir (Seville, Spain)

12:00pm-1:30pm

Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated week 8 results for the switch cohort

V. Sung, D. Stamler, D.O. Claassen (Birmingham, AL, USA)

12:00pm-1:30pm

Beneficial effect of L-theanine against 3-nitropropionic acid induced neurotoxicity in rats: Possible role of neurotransmitters and nitric oxide

P. Kumar, S. Jamwal (Moga, India)

12:00pm-1:30pm

CAG repeat length and weight loss in pre-manifest Huntington’s disease

C.F. Kutz, L.J. Adams (Colorado Springs, CO, USA)

12:00pm-1:30pm

Cerebellar gray matter alterations in Huntington disease: A voxel-based morphometry study

P. Azevedo, R. Guimarães, L. Piovesana, C. Piccinin, M.C. Arci, L. Villany, L. Campos, G. Pinheiro, J. Zuiane, A. Amato Filho, F. Cendes, Í. Lopes-Cendes, A. D'Abreu (Campinas, Brazil)

12:00pm-1:30pm

Clinical and behavioral features in carriers of intermediate length alleles of HTT gene. A case series of Mexican population

M.A. Ramírez-García, D.J. Dávila-Ortiz de Montellano, P. Yescas-Gómez, A. Ochoa-Morales, C. Boll, M.E. Alonso-Vilatela (Mexico City, Mexico)

12:00pm-1:30pm

Clinical and neuroimaging correlations in early manifest Huntington’s disease patients: Default mode network properties according to resting-state functional MRI

Y.A. Seliverstov, E.V. Seliverstova, S.A. Klyushnikov, R.N. Konovalov, S.N. Illarioshkin (Moscow, Russia)

12:00pm-1:30pm

Clinical presentation and genetic characteristics of Huntingtons disease in Croatia: Thirty years of experience

M. Relja, I. Jurjevic, K. Blazina, V. Miletic, N. Klepac (Zagreb, Croatia)

12:00pm-1:30pm

Cognitive impairment in Huntington’s disease

N. Kamble, N. Netravathi, K. Kumar, S. Jain, P.K. Pal (Bangalore, India)

12:00pm-1:30pm

Communication and language skills in Huntington’s disease

Y. Manor, D. Shpunt, S. Naor, L. Frydman, A. Gad, A. Ezra, A. Migirov, J. Knaani, A. Socher, T. Gurevich (Tel-Aviv, Israel)

12:00pm-1:30pm

Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging

M. Kronenbuerger, J. Hua, C.A. Ross (Baltimore, MD, USA)

12:00pm-1:30pm

CSF inflammatory and cell death biomarkers in Huntington’s disease – An exploratory cross-sectional study

F.B. Rodrigues, L. Byrne, S.J. Tabrizi, H. Zetterberg, E. Wild (London, United Kingdom)

12:00pm-1:30pm

Dysphagia in early stage Huntington’s disease (HD) – Pilot observations from a multimodal imaging study

I. Trender-Gerhard, E. Michou, A. Gerhard, D. Craufurd, S. Hamdy, K. Herholz (Manchester, United Kingdom)

12:00pm-1:30pm

Dysregulations of GABAergic neurotransmission in Huntington’s disease brain

Y.T. Hsu, Y.G. Chang, H.M. Chen, Y. Chern (Taichung, Taiwan)

12:00pm-1:30pm

Emotional facial EMG responses are affected in Huntington’s disease

C.C. Kordsachia, I. Labuschagne, J. Stout (St. Kilda, Australia)

12:00pm-1:30pm

Enroll-HD: A global clinical research platform for Huntington’s disease

T.A. Mestre, C. Fitzer-Attas, J. Giuliano, B. Landwehrmeyer, C. Sampaio (Ottawa, Canada)

12:00pm-1:30pm

Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease

D.O. Claassen, P. Donga, S. Rajagopalan, L.M. De Boer, B. Carroll, S. Gandhi (Nashville, TN, USA)

12:00pm-1:30pm

Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study

S.A. Frank, D.O. Claassen, S. Janicki, D. Oakes, D. Stamler, V. Sung, C. Vaughn, C.M. Testa, On behalf of First-HD HSG Investigators (Boston, MA, USA)

12:00pm-1:30pm

Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD

C.M. Testa, D.O. Claassen, D. Oakes, D. Stamler, V. Sung, S. Frank, On behalf of the First-HD HSG Investigators (Richmond, VA, USA)

12:00pm-1:30pm

Fast and simple non-invasive screening tool for mitochondrial changes in Huntington’s disease

P. Dušek, M. Rodinová, I. Lišková, E. Trefilová, Z. Ellederová, J. Klempír, J. Roth, H. Hansíková (Prague, Czech Republic)

12:00pm-1:30pm

Fifteen years of clinical trials in Huntington’s disease: Too many clinical trial failures

A.M. Travessa, F.B. Rodrigues, T.A. Mestre, C. Sampaio, J.J. Ferreira (Lisboa, Portugal)

12:00pm-1:30pm

Huntington disease phenocopies or misdiagnosis: A black South African cohort

F.K. Baine, A. Krause (Johannesburg, South Africa)

12:00pm-1:30pm

Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the FIRST-HD and TETRA-HD trials

D.O. Claassen, B. Carroll, L.M. De Boer, E. Wu, R. Ayyagari, S. Gandhi, D. Stamler (Nashville, TN, USA)

12:00pm-1:30pm

Interleaved pro- and anti-saccade performance in Huntington’s disease

I. Vaca-Palomares, J. Fernandez-Ruiz, B. Coe, D.P. Munoz (Kingston, ON, Canada)

12:00pm-1:30pm

Magnetic resonance imaging and pyramidal impairment in Huntington disease

A. Sanguinetti, S. Lescano, M. Cesarini, J. Etcheverry, E. Gatto (Buenos Aires, Argentina)

12:00pm-1:30pm

Maintenance of balance function in patients with HD treated with deutetrabenazine, as measured by Berg balance test (BBT) in First-HD

D.O. Claassen, D. Oakes, D. Stamler, V. Sung, C.M. Testa, S. Frank, On behalf of the First-HD HSG Investigators (Nashville, TN, USA)

12:00pm-1:30pm

Neurophysiological evidence of posterior-cortical alterations in premanifest Huntington’s: An event-related brain potentials study of face and face-like objects processing

S. Martinez-Horta, J. Perez-Perez, A. Horta-Barba, R. Fernandez-Bobadilla, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm

Neuroprotective potential of L-theanine against excitotoxic neuronal death induced by quinolinic acid: Possible neurotransmitters and nitric oxide modulation mechanism

S. Jamwal, P. Kumar (Moga, India)

12:00pm-1:30pm

Predictors of quality of life in Huntington’s disease. A longitudinal observational study

A. Brás, F. Júlio, M. Sousa, F. Blanco, C. Januário (Coimbra, Portugal)

12:00pm-1:30pm

Program evaluation empowerment of people with Huntington’s disease (HD) and their families: Using goal attainment scaling (GAS)

D. Alburquerque, N. Rojas, S. Tapia, P. Reyes, C. Silva, P. Chana-Cuevas (Santiago, Chile)

12:00pm-1:30pm

Psychosis in Huntington’s disease

J. Perez-Perez, S. Martinez-Horta, M. Carceller, J. Pagonabarraga, A. Horta, R. Fernandez-Bobabilla, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm

Specific in-patient’s rehabilitation improves postural and gait instability in Huntington’s disease

L. Brabcová, J. Roth, O. Horácek, M. Kolárová, H. Bozková, J. Rusz, P. Košková, K. Lísalová, F. Jancok, J. Klempír, E. Ruzicka, H. Brozová (Beroun, Czech Republic)

12:00pm-1:30pm

Strategies for a high quality data in an observational longitudinal study: Enroll-HD experience

N. Gonçalves, D. Abreu, R. Lobo, J. Giuliano, T. Mestre, J.J. Ferreira, C. Fitzer-Attas, B. Landwehrmeyer, C. Sampaio (Lisbon, Portugal)

12:00pm-1:30pm

Striatal molecular alterations in Huntington’s disease gene expansion carriers: A systematic review and meta-analysis of PET studies

F. Niccolini, G. Pagano, P. Fusar-Poli, A. Wood, L. Mrzljak, C. Sampaio, M. Politis (London, United Kingdom)

12:00pm-1:30pm

Suicide attempts and Huntington’s disease: Perseveration, not just impulsivity

O.C. Roman, J.G. Stovall, D.O. Claassen (Nashville, TN, USA)

12:00pm-1:30pm

Swallowing disorders characteristics and the relation to cognitive level, disease duration and disease severity in patients with Huntington’s disease

Y. Manor, D. Shpunt, N. Avniel, S. Assa, Y. Torner, A. Gad, A. Ezra, J. Knaani, A. Socher, Y. Oestriecher-Kedem, T. Gurevich (Tel Aviv, Israel)

12:00pm-1:30pm

Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report

K. Giehl, K. Reetz, I. Dogan, C. Werner, J.B. Schulz, A. Drzezga, T. van Eimeren (Köln, Germany)

12:00pm-1:30pm

Temporal course of the total motor score in Huntington disease

P. Auinger, T.J. Felong, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulos, C. Venuto, R. Dorsey (Rochester, NY, USA)

12:00pm-1:30pm

Temporal course of the UHDRS chorea score in Huntington disease

T.J. Felong, P. Auinger, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulos, C. Venuto, R. Dorsey (Rochester, NY, USA)

12:00pm-1:30pm

The assessment of quality of life in patients with early and moderately advanced Huntington disease

N. Szejko, L. Milanowski, A. Gogol, Z. Jamrozik, P. Janik (Warsaw, Poland)

12:00pm-1:30pm

The effects of gait and balance training on walking economy in early and mid stage Huntington’s disease

J.L. Kubica, J. Szymura, E. Mirek, M. Filip, M. Wiecek, M. Maciejczyk, M. Rudzinska, U. Pustulka-Piwnik, J. Stozek, S. Pasiut (Krakow, Poland)

12:00pm-1:30pm

Tractography study of individuals with mutation for Huntington’s disease in symptomatic and pre-symptomatic phases

R.A. Saba, J. Yared, T. Doring, V. Borges, L.B. Barcelos, H.B. Ferraz (São Paulo, Brazil)

12:00pm-1:30pm

Verbatim patient-reported outcomes and trails making test B (TMT-B) performance in the REACH2HD trial

J.L. Purks, A. Zeymo, N.M. Shara, K.E. Anderson, I. Shoulson (Washington, DC, USA)